NASDAQ:FOLD Amicus Therapeutics (FOLD) Stock Price, News & Analysis → get a piece of the profit from this land (From True Market Insiders) (Ad) Free FOLD Stock Alerts $9.57 +0.07 (+0.74%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$9.34▼$9.5950-Day Range$9.04▼$12.1352-Week Range$9.02▼$14.57Volume2.15 million shsAverage Volume3.01 million shsMarket Capitalization$2.83 billionP/E RatioN/ADividend YieldN/APrice Target$17.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Amicus Therapeutics alerts: Email Address Amicus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside82.9% Upside$17.50 Price TargetShort InterestHealthy9.71% of Shares Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.46Based on 13 Articles This WeekInsider TradingSelling Shares$176,025 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.19) to $0.22 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.54 out of 5 starsMedical Sector126th out of 920 stocksPharmaceutical Preparations Industry47th out of 429 stocks 4.4 Analyst's Opinion Consensus RatingAmicus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAmicus Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amicus Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.71% of the outstanding shares of Amicus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAmicus Therapeutics has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Amicus Therapeutics has recently decreased by 8.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmicus Therapeutics does not currently pay a dividend.Dividend GrowthAmicus Therapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmicus Therapeutics has received a 63.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Fabry disease medication", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Amicus Therapeutics is -1.28. Previous Next 3.0 News and Social Media Coverage News SentimentAmicus Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Amicus Therapeutics this week, compared to 4 articles on an average week.Search Interest6 people have searched for FOLD on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows1 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $176,025.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Amicus Therapeutics is held by insiders.Read more about Amicus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amicus Therapeutics are expected to grow in the coming year, from ($0.19) to $0.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amicus Therapeutics is -19.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amicus Therapeutics is -19.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmicus Therapeutics has a P/B Ratio of 21.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amicus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBible Shocker: Have You Seen Elon Musk’s Miracle?Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story… About Amicus Therapeutics Stock (NASDAQ:FOLD)Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Read More FOLD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FOLD Stock News HeadlinesMay 4, 2024 | insidertrades.comInsider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells 7,500 Shares of StockMay 16 at 4:28 AM | americanbankingnews.comAmicus Therapeutics (NASDAQ:FOLD) Stock Rating Upgraded by GuggenheimMay 14, 2024 | msn.comGuggenheim Upgrades Amicus Therapeutics (FOLD)May 14, 2024 | markets.businessinsider.comEvaluating Amicus Therapeutics: Insights From 6 Financial AnalystsMay 14, 2024 | americanbankingnews.comAmicus Therapeutics (NASDAQ:FOLD) Given New $19.00 Price Target at Morgan StanleyMay 14, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates "Hold" Rating for Amicus Therapeutics (NASDAQ:FOLD)May 14, 2024 | americanbankingnews.comBank of America Cuts Amicus Therapeutics (NASDAQ:FOLD) Price Target to $13.00May 13, 2024 | americanbankingnews.comAnalysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $20.00May 12, 2024 | americanbankingnews.comUBS Group Lowers Amicus Therapeutics (NASDAQ:FOLD) Price Target to $19.00May 10, 2024 | finance.yahoo.comAmicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...May 10, 2024 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call TranscriptMay 9, 2024 | investorplace.comFOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | washingtonpost.comAmicus Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comAmicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate UpdatesMay 8, 2024 | globenewswire.comAmicus Therapeutics to Present at the Bank of America 2024 Health Care ConferenceMay 8, 2024 | barrons.comAmicus Therapeutics Inc.May 1, 2024 | globenewswire.comAmicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024April 14, 2024 | nasdaq.comAmicus Therapeutics Becomes Oversold (FOLD)March 30, 2024 | msn.comNevada’s Lee joins on to Amicus Brief in SCOTUS abortion caseMarch 29, 2024 | msn.comNevada’s Lee, Cortez Masto join on to Amicus Brief in SCOTUS abortion caseMarch 20, 2024 | globenewswire.comAmicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) ReportMarch 16, 2024 | ca.finance.yahoo.comFOLD Jul 2024 12.000 callMarch 7, 2024 | finance.yahoo.comFOLD Oct 2024 12.000 callMarch 7, 2024 | finance.yahoo.comFOLD Jan 2025 12.000 putMarch 7, 2024 | finance.yahoo.comFOLD Jul 2024 9.000 putSee More Headlines Receive FOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/19/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:FOLD CUSIP03152W10 CIK1178879 Webwww.amicusrx.com Phone(215) 921-7600Fax609-662-2001Employees517Year Founded2002Price Target and Rating Average Stock Price Target$17.50 High Stock Price Target$22.00 Low Stock Price Target$13.00 Potential Upside/Downside+82.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,580,000.00 Net Margins-34.73% Pretax Margin-33.17% Return on Equity-77.08% Return on Assets-13.79% Debt Debt-to-Equity Ratio2.97 Current Ratio3.03 Quick Ratio2.61 Sales & Book Value Annual Sales$399.36 million Price / Sales7.10 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book21.75Miscellaneous Outstanding Shares296,200,000Free Float289,683,000Market Cap$2.83 billion OptionableOptionable Beta0.80 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Bradley L. Campbell M.B.A. (Age 48)CEO, President & Director Comp: $984.09kMs. Ellen S. Rosenberg (Age 61)Chief Legal Officer & Corporate Secretary Comp: $733.94kMr. David M. Clark (Age 49)Chief People Officer Comp: $701.39kDr. Jeffrey P. Castelli (Age 52)Chief Development Officer Comp: $709.64kMr. Simon Nicolas Reade Harford (Age 64)Chief Financial Officer Ms. Samantha Prout (Age 46)Chief Accounting Officer & Controller Dr. Jill Weimer Ph.D.Chief Science OfficerAndrew FaughnanSenior Director of Investor RelationsMr. Patrik S. Florencio Esq.Global Chief Compliance & Risk OfficerMs. Diana MooreHead of Global Corporate CommunicationsMore ExecutivesKey CompetitorsGeronNASDAQ:GERNTurning Point TherapeuticsNASDAQ:TPTXLigand PharmaceuticalsNASDAQ:LGNDDynavax TechnologiesNASDAQ:DVAXPerrigoNYSE:PRGOView All CompetitorsInsiders & InstitutionsArtal Group S.A.Sold 3,514,588 shares on 5/17/2024Ownership: 0.342%Comerica BankSold 9,544 shares on 5/17/2024Ownership: 0.032%Walleye Trading LLCSold 8,700 shares on 5/17/2024Ownership: 0.000%Silvercrest Asset Management Group LLCBought 16,033 shares on 5/16/2024Ownership: 0.127%California State Teachers Retirement SystemSold 9,452 shares on 5/16/2024Ownership: 0.077%View All Insider TransactionsView All Institutional Transactions FOLD Stock Analysis - Frequently Asked Questions Should I buy or sell Amicus Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FOLD shares. View FOLD analyst ratings or view top-rated stocks. What is Amicus Therapeutics' stock price target for 2024? 7 Wall Street research analysts have issued twelve-month target prices for Amicus Therapeutics' stock. Their FOLD share price targets range from $13.00 to $22.00. On average, they anticipate the company's stock price to reach $17.50 in the next year. This suggests a possible upside of 82.9% from the stock's current price. View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts. How have FOLD shares performed in 2024? Amicus Therapeutics' stock was trading at $14.19 on January 1st, 2024. Since then, FOLD shares have decreased by 32.6% and is now trading at $9.57. View the best growth stocks for 2024 here. When is Amicus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our FOLD earnings forecast. How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.04. The biopharmaceutical company earned $110.40 million during the quarter, compared to the consensus estimate of $111.19 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 77.08% and a negative net margin of 34.73%. Amicus Therapeutics's revenue for the quarter was up 27.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.18) EPS. What ETFs hold Amicus Therapeutics' stock? ETFs with the largest weight of Amicus Therapeutics (NASDAQ:FOLD) stock in their portfolio include Sovereigns Capital Flourish Fund (SOVF), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC).iShares Biotechnology ETF (IBB). What guidance has Amicus Therapeutics issued on next quarter's earnings? Amicus Therapeutics updated its FY 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $499.2 million-$519.2 million, compared to the consensus revenue estimate of $530.0 million. What is John F. Crowley's approval rating as Amicus Therapeutics' CEO? 21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Amicus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX). Who are Amicus Therapeutics' major shareholders? Amicus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.52%), Janus Henderson Group PLC (4.66%), Redmile Group LLC (4.48%), William Blair Investment Management LLC (3.89%), Healthcare of Ontario Pension Plan Trust Fund (0.73%) and Price T Rowe Associates Inc. MD (0.47%). Insiders that own company stock include Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout. View institutional ownership trends. How do I buy shares of Amicus Therapeutics? Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FOLD) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.